Avalide advisory committee
FDA's Cardio-Renal Drugs Advisory Committee will meet April 18 to review an sNDA for Bristol-Myers Squibb's antihypertensive agent Avalide. Bristol is seeking approval for first-line use of Avalide, a combination of Bristol's angiotensin II receptor blocker Avapro and the diuretic hydrochlorothiazide, in hypertensive patients unlikely to achieve blood pressure goals on one drug. The committee will be asked to consider what constitutes adequate data to support such a claim and how the information can be most usefully displayed in the labeling. Avalide was approved by FDA in August 1998 (1"The Pink Sheet" May 17, 1999, p. 25). The meeting will be held at the CDER advisory committee conference room, 5630 Fishers Lane, Rockville, Md., beginning at 8 a.m...
You may also be interested in...
Average wholesale price for 150 mg irbesartan/12.5 mg hydrochlorothiazide tablets will be $1.51. AWP for the 300 mg irbesartan/12.5 mg hydrochlorothiazide tablets will be $1.57. The companies began shipping the product in early May. Avalide, a combination of the companies' angiotensin II receptor blocker Avapro and the diruretic hydrochlorothiazide, was approved by FDA in August 1998
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.